Student and Faculty Publications
Publication Date
10-31-2023
Journal
Oncotarget
Abstract
Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. Herein, we discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC). The preclinical efficacy of additional agents is also discussed, particularly the pan-HER inhibitor poziotinib.
Keywords
Humans, Female, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Alleles, Receptor, ErbB-2, metastasis, poziotinib, HER2, neratinib, invasive lobular breast carcinoma
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons
Comments
PMID: 37921670